"...imaging tumors early can improve how clinicians develop personalized treatment plans for each patient."

"Once we identified the mechanism causing the colitis, we could then develop ways to overcome this problem..."

Glioblastoma is one of the most treatment-resistant cancers. A new study offers clues as to how it can aggressively resist immunotherapy.

Dana-Farber Cancer Institute researcher details promise, peril of CAR T-cell therapy, which enlists body’s immune system to fight disease.

In mouse models of different cancers, a new drug slowed tumor growth, extended lifespan, and boosted the efficacy of immunotherapy.

Fusing a molecular tail onto the engineered T cells used in immunotherapy can inhibit their proclivity to attack each other, say researchers.

"We hypothesized that the newer treatment would turn out to be most beneficial for patients, but the magnitude of the benefit exceeded our expectations."

From cancer immunotherapy and antibiotics to GMO crops and pandemic surveillance, gain of function is a cornerstone of basic research.

There is no one-size-fits-all approach to treating cancer. Understanding how cancer cells evolve could help researchers develop more effective drugs.